Cargando…

BRD4-mediated repression of p53 is a target for combination therapy in AML

Acute myeloid leukemia (AML) is a typically lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, most AML retain wild-type TP53, encoding the pro-apoptotic tumor suppressor p53. MDM2 inhibitors (MDM2i), which activate wild-type p53, and BET inhibitors (BE...

Descripción completa

Detalles Bibliográficos
Autores principales: Latif, Anne-Louise, Newcombe, Ashley, Li, Sha, Gilroy, Kathryn, Robertson, Neil A., Lei, Xue, Stewart, Helen J. S., Cole, John, Terradas, Maria Terradas, Rishi, Loveena, McGarry, Lynn, McKeeve, Claire, Reid, Claire, Clark, William, Campos, Joana, Kirschner, Kristina, Davis, Andrew, Lopez, Jonathan, Sakamaki, Jun-ichi, Morton, Jennifer P., Ryan, Kevin M., Tait, Stephen W. G., Abraham, Sheela A., Holyoake, Tessa, Higgins, Brian, Huang, Xu, Blyth, Karen, Copland, Mhairi, Chevassut, Timothy J. T., Keeshan, Karen, Adams, Peter D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801601/
https://www.ncbi.nlm.nih.gov/pubmed/33431824
http://dx.doi.org/10.1038/s41467-020-20378-8

Ejemplares similares